About gastrointestinal OTC drugs
OTC drugs are medications that do not require a prescription. In contrast, prescription drugs can be sold only to consumers having a legal prescription. OTC drugs are carefully chosen by regulatory agencies to ensure their safety and efficacy. Gastrointestinal OTC drugs can be bought off-the-shelf. Gastrointestinal OTC drugs are used for indications such as GERD, vomiting, constipation, diarrhea, and flatulence. Some of the OTC drugs that are available for the treatment of gastrointestinal diseases are laxatives, anti-flatulents, H2-antaginists, anti-diarrheals, PPIs, and anti-emetics. The OTC drugs are not bound by regulatory guidelines, but need to comply with the drug monograph of a country.
TechNavio's analysts forecast the global gastrointestinal OTC drugs market to grow at a CAGR of 1.48% over the period 2014-2019.
Covered in this report
This report covers the present scenario and the growth prospects of the global gastrointestinal OTC drugs market for the period 2015-2019. To calculate the market size, the report considers revenue from the sales of various OTC drugs available in the market for the management of gastrointestinal disorders such as:
Technavio Announces the Publication of its Research Report – Global Gastrointestinal OTC Drugs Market 2015-2019
Technavio recognizes the following companies as the key players in the Global Gastrointestinal OTC Drugs Market 2015-2019: AG, GlaxoSmithKline plc, Johnson & Johnson Ltd., Perrigo Co. plc, Pfizer Inc. and Procter & Gamble Co.
Other Prominent Vendors in the market are: Abbott, Boehringer Ingelheim, C.B. Fleet, Daewoong, Eisai, Nestle, Omega, Purdue Pharma, Reckitt Benckiser, Sanofi, Taisho, Takeda Pharmaceutical and Teva Pharmaceutical.
Commenting on the report, an analyst from Technavio’s team said: “Strategic alliances among vendors that lead to market consolidation are expected to have a positive impact on market growth during the forecast period. Collaborations among the leading vendors help them to obtain an edge over smaller companies.”
According to the report, the increased patient population has a positive impact on market growth. The growing incidence of gastrointestinal disorders and a rise in the geriatric population has led to an increase in the overall patient population. Patients undergo self-diagnosis and self-medication leading to increased consumption of OTC drugs.
Further, the report states that increased expenditure on advertisements of the drugs hinders the growth of the market.
AG, GlaxoSmithKline plc, Johnson & Johnson Ltd., Perrigo Co. plc, Pfizer Inc. and Procter & Gamble Co., Abbott, Boehringer Ingelheim, C.B. Fleet, Daewoong, Eisai, Nestle, Omega, Purdue Pharma, Reckitt Benckiser, Sanofi, Taisho, Takeda Pharmaceutical and Teva Pharmaceutical.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook